Table 4. Distributions of BRAF mutations in the selected patients.

Clinical characteristic	n	BRAF mutation (n%)	Univariate OR (95%CI)	Multivariate OR (95%CI)
Total	495	143(28.9%)
sex
women	184	32(17.4%)	1(reference)	1(reference)
men	311	45(14.4%)	0.8(0.5-1.3)	0.7(0.4-1.2)
age
≤53	137	15(10.9%)	1(reference)	1(reference)
54-60	124	24(19.4%)	1.4(0.7-2.8)	1.8(0.8-4.0)
61-66	119	21(17.6%)	1.4(0.7-2.8)	1.3(0.6-3.0)
>66	115	17(14.8%)	1.1(0.5-2.1)	1.0(0.4-2.2)
location
Right colon	149	18(12.1%)	1(reference)	1(reference)
Left colon	346	59(17.1%)	1.5(0.85-2.6)	1.6(0.9-2.7)
histology
TA	155	8(5.2%)	1(reference)	1(reference)
TVA	123	10(8.1%)	1.5(0.6-4.3)	1.8(0.7-4.7)
SA	52	26(50.0%)	18.4(7.5-45)	20.6(8.2-51.8)
VA	7	4(57.0%)	24.5(4.7-128.5)	26.2(4.7-144.2)
HPs	65	24(36.9%)	10.8(4.5-25.7)	11.9(4.9-29.0)
HGIN	93	5(5.3%)	1.0(0.3-3.3)	1.1(0.3-3.5)

TA= Tubular adenoma, TVA= Tubulovillous adenoma, SA= Serrated adenoma, VA= Villous adenoma, HPs= Hyperplastic polyps, HGIN= High grade intraepithelial neoplasia